Autologous NK cell immunotherapy
Expanded natural-killer cells, given after surgery to widen the immune margin.
Natural killer cells recognise stressed and transformed cells without needing a specific antigen match. In this protocol they are collected, expanded in the laboratory over several weeks, and reinfused in cycles.
It is positioned after definitive surgery, where the goal is to reduce the chance of recurrence rather than to shrink a measurable mass. Whether it is appropriate depends on staging, pathology and what has already been given.
What it does not do
- The evidence base is strongest for recurrence risk, not for treating bulk disease.
- Laboratory expansion takes weeks; the schedule has to be planned around it.
- Cell products are regulated differently in every country. Import and re-export are not possible — treatment happens here.
These limits are written by us, not by the hospital. If a provider presents this therapy without any of them, treat that as a warning sign.
| Indication | Post-operative recurrence prevention in selected solid tumours |
| Approved in | China — biomedical new-technology pathway |
| Status in China | Approved clinical translation project within the zone |
| Assessment required | Yes — physician assessment first |
| Delivered at | 1 hospital(s) |
Also in Oncology
BNCT
A targeted radiotherapy that delivers its dose cell-by-cell, sparing the tissue around it.
Histotripsy
Tumour tissue broken down by focused ultrasound — no incision, no needle, no radiation.
DC vaccine
A vaccine made from your own dendritic cells, trained against your own tumour markers.
Tell us the therapy by name, and we will check it.
Availability moves with batches and indications. A two-line enquiry is enough for us to confirm whether it is reachable this quarter.